{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-119762","form_type":"8-K","ticker":null,"cik":"0001654151","company_name":"Deciphera Pharmaceuticals, Inc.","filed_at":"2024-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.444817+00:00","generated_at":"2026-06-03T05:37:15.504407+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Deciphera to be acquired by Ono Pharmaceutical for $25.60/share in cash, ~$2.4B equity value","bullets":["Offer price $25.60/share cash, 74.7% premium over April 26 close of $14.65.","Tender offer for all shares; expected close Q3 2024, subject to antitrust and majority tender.","Stockholders owning ~28% of shares have agreed to tender in support agreements.","Deciphera will not host Q1 2024 earnings call; Form 10-Q to be filed in ordinary course.","Boards of both companies unanimously approved; Deciphera to operate as standalone Ono unit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-119762","json":"https://secwatch.observer/filing/0001193125-24-119762.json","markdown":"https://secwatch.observer/filing/0001193125-24-119762.md","text":"https://secwatch.observer/filing/0001193125-24-119762.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524119762/0001193125-24-119762-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524119762/d831713d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T05:37:15.504407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ec05ea91b83d904d0a04631a2ae0bbc41440e7f8","claim":"Deciphera Pharmaceuticals, Inc. entered into Agreement and Plan of Merger with Ono Pharmaceutical Co., Ltd. and Topaz Merger Sub, Inc. valued at $25.60 per share (effective 2024-04-29).","evidence_excerpt":"ion (the “ Company ” or “ Deciphera ”), Ono Pharmaceutical Co., Ltd., a Japanese company ( kabushiki kaishi ) (“ Parent ” or “ Ono ”), and Topaz Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”). Pursuant to the Merger Agreement, and upon the terms and subject to the conditions therein, Merger Sub will commence a cash tender offer (the “ Offer ”) to acquire all of the issued and outstanding shares of the common stock, par value $0.01 per share, of the Company (“ Company Common Stock ”), at a price per share of $25.60, net to the seller in cash, without interest and subject to any withholding of taxes required by applicable law.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1654151/000119312524119762/0001193125-24-119762-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Ono Pharmaceutical Co., Ltd. and Topaz Merger Sub, Inc."},{"label":"Value","value":"$25.60 per share"},{"label":"Effective","value":"2024-04-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}